Introduction
with mild to moderate hypertension. Indapamide (Lozol ® , Rhô ne-Poulenc Rorer Pharmaceuticals, Collegeville, PA, USA) is an indoline, thi-
Patients and methods
azide-like diuretic with a favourable benefit-to-risk ratio in low doses (2.5 mg and 1.25 mg).
Patients Initiation of antihypertensive drug therapy at the Two hundred and four patients were randomized to lowest possible dose is consistent with optimizing the double-blind treatment period, 103 to the indasafety as well as providing efficacy, especially in pamide 1.25 mg group and 101 to the placebo group. elderly patients who may have altered physiologic
One hundred and seventy-seven patients completed functions or concomitant disease processes.
the study, 92 (89%) in the indapamide 1.25 mg Although diuretics are generally well tolerated by group and 85 (84%) in the placebo group. The demoelderly patients, there exists the potential for hypographic characteristics of all randomized patients tensive, arrhythmic, or generalized adverse systemic are shown in Table 1 . responses to occur. In keeping with these concepts, this study was undertaken to evaluate the antihypertensive efficacy and safety of low-dose indapamide,
Inclusion criteria
Patients who were 65 years of age or older with mild to moderate essential hypertension (defined as untreated supine diastolic blood pressure (DBP) During the double-blind treatment period, patients were seen every 2 weeks at which time BP, heart rate, and body weight were measured. At weeks 0 and 4 fasting clinical laboratory parameters, screened for enrollment into this study. Other inclusion criteria were: biochemistry, haematology including serum chemistry, haematology, urinalysis, lipids, and electrolytes (week 4 only) were and urinalysis test results without clinically significant abnormalities; serum potassium levels within measured. A 12-lead ECG was repeated at week 0. At the final visit (week 8), patients had a complete the range of 3.4 to 5.4 mEq/L without potassium supplementation; and renal function parameters physical examination, a 12-lead ECG, and fasting clinical laboratory tests (haematology, biochemistry, within stable levels (BUN р24 mg/dL and creatinine р2.0 mg/dL). Patients were to have been previously lipids, and urinalysis). Adverse events and the use of concomitant medication were recorded throughon monotherapy treatment for hypertension or to have been newly diagnosed (no previous drug out the double-blind period. Generally, the investigator gave the patient potassium supplementation therapy) with hypertension.
Following an explanation of the study and related when the serum potassium level dropped below 3.4 mEq/L; however, this was based on the investiprocedures and prior to the screening visit, all patients were to have signed an Informed Consent gator's judgment. Form.
Statistical analysis Exclusion criteria
The primary and secondary efficacy analyses were carried out on the all-treated patient populations. Patients with malignant or severe hypertension, a disease state causing secondary hypertension, or
The primary efficacy variable was the mean change in supine DBP from double-blind baseline (week 0) patients previously treated with multiple drug therapy for hypertension were excluded from the study.
to the end of 8 weeks of therapy. Secondary efficacy criteria were the percentage of patients having a Also excluded from the study were patients with significant diseases of the cardiac conduction syssupine DBP р90 mm Hg, or a reduction of at least 10 mm Hg from double-blind baseline to the end of tem, premature ventricular beats considered clinically significant or requiring treatment, uncontrolled 8 weeks of therapy and to the last study assessment; the mean change from double-blind baseline to last congestive heart failure, stroke within 1 year with residual paresis or other neurologic impairment, sigstudy assessment in supine DBP; and the mean change from double-blind baseline to the end of 8 nificant renal or vascular disease, treatment with insulin or lithium, history of recent alcohol or drug weeks of therapy and to the last study assessment in supine systolic BP (SBP), and standing systolic abuse, or any clinically significant deviation from normal in either the physical exam or in laboraand DBP.
The significance of a centre by treatment intertory parameters.
action was investigated with a two-way analysis of variance model with centre, treatment group, and Design treatment by centre interaction effects at the conservative level of 10% for primary efficacy only. This was a multicentre, randomized study consisting of two periods: a single-blind placebo washTreatment comparisons were performed using a two-way analysis of variance model with main out period and a double-blind treatment period. Patients who met the entry criteria entered a 4-week effects of center and treatment group in supine and standing diastolic and SBPs to the end of 8 weeks mm Hg was observed in the indapamide 1.25 mg group compared to a mean decrease of 4.2 mm Hg of double-blind therapy and to the last study assessment. All efficacy comparisons of the treatment in the placebo group (Table 3) . Additionally, indapamide 1.25 mg was statistically (P р0.0029) more groups were two-sided at the 0.05 level of significance. Treatment comparisons using the Cochraneffective than placebo in reducing both standing diastolic and SBP. The respective mean decreases Mantel-Haenszel test, stratified by centre, were performed for a percentage of patients with a DBP р90 for standing diastolic and SBP, at week 8 were 7.7 mm Hg and 11.7 mm Hg in the indapamide 1.25 mg mm Hg at the end of the double-blind treatment period.
group compared to mean decreases of 4.5 mm Hg and 2.4 mm Hg in the placebo group. All safety analyses were based on the all-treated patient population. Descriptive statistics were used Indapamide 1.25 mg was more effective than placebo in producing a treatment response (decrease of to summarize safety variables. No formal statistical test of hypothesis was carried out. Treatment groups supine DBP р90 mm Hg or a reduction of at least 10 mm Hg from double-blind baseline to the end of were compared with counts and per cents for the incidence of adverse events, hypokalemia (defined 8 weeks of therapy). At week 8, the response rate in the indapamide 1.25 mg group was 55% (48/87) as a potassium level р3.4 mEq/L), death, premature discontinuation from study, concomitant medicompared to 37% (32/87) in the placebo group; this difference between treatment groups was statistications, and changes from double-blind baseline to the last study assessment relative to the normal cally significant (P = 0.020) ( Table 4) . When defining treatment response in terms of SBP reduction (р140 ranges for haematology and biochemistry parameters.
mm Hg), indapamide 1.25 mg was again more effective than placebo. At week 8, the indapamide Treatment groups were compared with descriptive statistics for mean changes from double-blind 1.25 mg group response rate was 32% (28/87) compared to 14% (12/87) in the placebo group; the difbaseline to the last study assessment for haematology and biochemistry parameters, ECG data, apiference between treatment groups was statistically significant (P = 0.002) ( Table 5 ). cal heart rate and body weight. Indapamide 1.25 mg was well tolerated in this elderly patient population. The incidence of all Results adverse events during the treatment period was slightly lower in the indapamide 1.25 mg group A total of 204 patients were randomized to the double-blind treatment period, 103 to the indapamcompared to the placebo group (31% vs 38%). The most frequently reported adverse event in the indaide 1.25 mg group and 101 to the placebo group. One hundred and seventy-seven patients completed the pamide 1.25 group and the placebo group was headache (5% vs 7%) ( Table 6 ). The incidence of drugstudy, 92 (89%) of the indapamide group and 85 (84%) of the placebo group. Twenty-seven patients related adverse events was similar between the indapamide 1.25 mg and placebo groups (9% vs 12%). (11 indapamide, 16 placebo) were prematurely discontinued from the study for the following reasons:
Of the drug-related adverse events, leg cramps were reported by the highest percentage of patients, 4% adverse events (4 indapamide, 6 placebo), ineffective therapy (1 indapamide, 6 placebo), protocol of the indapamide-treated patients. Five patients in the indapamide 1.25 mg treatment deviations (1 indapamide, 2 placebo), withdrawn consent (1 indapamide, 1 placebo), lost to follow-up group and six in the placebo treatment group were discontinued due to adverse events. Seven patients (2 indapamide), and other (2 indapamide, 1 placebo).
reported serious adverse events, two in the indapamide 1.25 mg group and five in the placebo group. Indapamide 1.25 mg was statistically (P = 0.0037) more effective than placebo in reducing supine DBP.
None of the serious adverse events were considered by the investigator to be related to study drug At week 8, a mean decrease of 8.2 mm Hg was observed in the indapamide 1.25 mg group comadministration. One patient in the indapamide 1.25 mg treatment group died due to underlying pared to a mean decrease of 5.3 mm Hg in the placebo group (Table 2) .
arteriosclerosis as assessed by the investigator, and one patient in the placebo treatment group died of Indapamide 1.25 mg was also statistically (P = 0.0028) more effective than placebo in reducing myocardial infarction. In both cases, the cause of death was not related to study drug administration. supine SBP. At week 8, a mean decrease of 10.1 Slightly larger mean changes in laboratory para- the changes were considered to be clinically meaningful (Table 7) . With respect to changes in laboratory parameters relative to the normal range, the majority of patients in both treatment groups had Ten of 100 (10%) patients with both baseline and endpoint potassium values in the indapamide laboratory values that were within the normal range at both the baseline and endpoint evaluations. Thir-1.25 mg treatment group were hypokalaemic at least once during the double-blind treatment period. Of teen indapamide and five placebo patients had triglyceride values that shifted from within the normal these 10 patients, two were hypokalaemic and eight were normokalaemic at endpoint. Neither of the two range at baseline to above the normal range at endpoint, and 13 indapamide and two placebo patients who were hypokalaemic at endpoint received potassium supplementation. of the eight patients had uric acid values that shifted from within the normal range at baseline to above the norpatients who were normokalaemic at endpoint, three required potassium supplementation and five mal range at endpoint. In addition, seven indapamide and one placebo patient had HDL cholesterol returned to normal levels without potassium supplements. The effect of potassium supplementation values that shifted from within the normal range at baseline to below the normal range at endpoint.
on mean potassium values was minimal. None of the patients were hypokalaemic at least once during the double-blind treatment period. Only two of the patients with hypokalaemic occurrences were still 98 placebo-treated patients were hypokalaemic during the double-blind treatment interval.
hypokalemic at endpoint; neither patient received potassium supplementation. For patients with arrhythmias or underlying Discussion ischaemic disease, a reduction in potassium loss could be potentially of clinical importance.
11,12
Treatment of hypertension in the elderly patient population presents challenges, in part due to the However, studies that used 24-and 48-hour ECG monitoring do not support this assumption, as there presence of concomitant diseases, including heart failure, chronic obstructive pulmonary disease, diahas been no consistent evidence of increased arrhythmia associated with thiazide-induced hypobetes, gout, peripheral vascular disease, and renal failure. Several treatment options are available for kalaemia. 13, 14 Hypokalaemia has been associated with the occurrence of ventricular arrhythmias durthe elderly hypertensive patient population, including treatment with diuretic-based regimens. The ing myocardial infarction. 15, 16 Other patient populations that could benefit from therapy that has a efficacy of thiazide diuretics in reducing BP in the elderly patient population has been supported by minimal effect on electrolytes are those with recent myocardial infarctions or patients on digitalis therthe results of several clinical trials. [1] [2] [3] [4] [5] Although thiazides are generally well-tolerated in the elderly, 1, 2, 6 apy. 17, 18 In addition, the 1.25 mg dose may be particularly suited to elderly patients who are generally there is evidence that they produce short-term 
